clinical trial · NCT06932263
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
AstraZeneca·phase2·recruiting·n = 540
AsthmaTozorakimabPlacebo
brief summary
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
started
Mar 26, 2025
primary completion
Jun 24, 2027
completion
Mar 16, 2028
last updated
Apr 9, 2026
official title
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol